TW202028179A - 胺基酸化合物及使用方法 - Google Patents
胺基酸化合物及使用方法 Download PDFInfo
- Publication number
- TW202028179A TW202028179A TW108136254A TW108136254A TW202028179A TW 202028179 A TW202028179 A TW 202028179A TW 108136254 A TW108136254 A TW 108136254A TW 108136254 A TW108136254 A TW 108136254A TW 202028179 A TW202028179 A TW 202028179A
- Authority
- TW
- Taiwan
- Prior art keywords
- tetrahydro
- naphthyridin
- ethyl
- homoserine
- cyclobutyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 512
- -1 Amino acid compounds Chemical class 0.000 title claims description 306
- 150000001875 compounds Chemical class 0.000 claims abstract description 807
- 150000003839 salts Chemical class 0.000 claims abstract description 334
- 108010044426 integrins Proteins 0.000 claims abstract description 148
- 102000006495 integrins Human genes 0.000 claims abstract description 148
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 36
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 34
- 230000004761 fibrosis Effects 0.000 claims abstract description 33
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract description 27
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 22
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 291
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 229
- 229910052736 halogen Inorganic materials 0.000 claims description 178
- 150000002367 halogens Chemical class 0.000 claims description 145
- 125000001072 heteroaryl group Chemical group 0.000 claims description 135
- 125000000623 heterocyclic group Chemical group 0.000 claims description 95
- 125000003118 aryl group Chemical group 0.000 claims description 92
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 83
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 82
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 81
- 201000010099 disease Diseases 0.000 claims description 81
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 79
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 79
- 229910052805 deuterium Inorganic materials 0.000 claims description 79
- 230000003176 fibrotic effect Effects 0.000 claims description 62
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 51
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 47
- 125000005843 halogen group Chemical group 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000002253 acid Substances 0.000 claims description 41
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 40
- 230000002401 inhibitory effect Effects 0.000 claims description 39
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 32
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 31
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims description 29
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 23
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 23
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 15
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 15
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 13
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 13
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 13
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 12
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 12
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 208000020832 chronic kidney disease Diseases 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 11
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 10
- 206010039710 Scleroderma Diseases 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000002393 azetidinyl group Chemical group 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 210000000013 bile duct Anatomy 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 5
- 230000009787 cardiac fibrosis Effects 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 206010004664 Biliary fibrosis Diseases 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 206010050207 Skin fibrosis Diseases 0.000 claims description 4
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 3
- URUKMUHHWWCNKS-UHFFFAOYSA-N 2-cyclohexyloxane Chemical compound C1CCCCC1C1OCCCC1 URUKMUHHWWCNKS-UHFFFAOYSA-N 0.000 claims description 3
- PZTRNMQIYAZMCX-UHFFFAOYSA-N 2-cyclooctyloxocane Chemical group C1CCCCCCC1C1OCCCCCC1 PZTRNMQIYAZMCX-UHFFFAOYSA-N 0.000 claims description 3
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 3
- 201000005271 biliary atresia Diseases 0.000 claims description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 210000005228 liver tissue Anatomy 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- BULPNSGUAZZZCF-PLYFQIMLSA-N (2S)-2-(4,5,6,7-tetrahydro-1H-indazole-7-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1CCCC=2C=NNC1=2)C(=O)O BULPNSGUAZZZCF-PLYFQIMLSA-N 0.000 claims description 2
- ZYFFBSMCHLIDHV-UYJHFMRCSA-N (2S)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[(1,1,1-trifluoro-2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)OC(C(F)(F)F)(C)C)C(=O)O ZYFFBSMCHLIDHV-UYJHFMRCSA-N 0.000 claims description 2
- YUAWJDYPCCAFGV-UDJZJCJKSA-N (2S)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[(2,4,6-trimethylpyrimidine-5-carbonyl)amino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C=1C(=NC(=NC=1C)C)C)C(=O)O YUAWJDYPCCAFGV-UDJZJCJKSA-N 0.000 claims description 2
- DGRBCGJJVUNTFQ-WQMGSUCASA-N (2S)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[[1-[3-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1(CC1)C1=CC(=CC=C1)OC(F)(F)F)C(=O)O DGRBCGJJVUNTFQ-WQMGSUCASA-N 0.000 claims description 2
- NBUHEBZCMGQXGW-UHFFFAOYSA-N 2-(2-ethylbutanoylamino)-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]hexanoic acid Chemical compound C(C)C(C(=O)NC(C(=O)O)CCCCOCCC1=NC=2NCCCC=2C=C1)CC NBUHEBZCMGQXGW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- GDSQTWDUCDSZEY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indazole Chemical group C1CCCC2=C1C=NN2 GDSQTWDUCDSZEY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims description 2
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- OIWOCFOJDONMTF-GQOXECLESA-N C(#N)CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound C(#N)CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C OIWOCFOJDONMTF-GQOXECLESA-N 0.000 claims description 2
- LKLBOTZGAZOMCD-JITJBCMDSA-N C(C)(=O)N1CC(C1)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)N1CC(C1)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 LKLBOTZGAZOMCD-JITJBCMDSA-N 0.000 claims description 2
- MUBOCXVSBAJANH-BZCIDDNGSA-N C(C)(=O)NCC(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)NCC(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 MUBOCXVSBAJANH-BZCIDDNGSA-N 0.000 claims description 2
- VOVWQSSPALFHDP-FNEQHPHYSA-N C(C)(C)(C)C1=CC(=NC(=N1)C1=CC=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=CC(=NC(=N1)C1=CC=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VOVWQSSPALFHDP-FNEQHPHYSA-N 0.000 claims description 2
- QBTAANARAWHSQC-UDJZJCJKSA-N C(C)C1(CCC(CC1)(F)F)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)C1(CCC(CC1)(F)F)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 QBTAANARAWHSQC-UDJZJCJKSA-N 0.000 claims description 2
- CBILFTGRPMBJNY-MTQWGCILSA-N CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC1=CC=CC=C1)C Chemical compound CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC1=CC=CC=C1)C CBILFTGRPMBJNY-MTQWGCILSA-N 0.000 claims description 2
- DMBMKRSKYQFQOU-GQOXECLESA-N CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C Chemical compound CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C DMBMKRSKYQFQOU-GQOXECLESA-N 0.000 claims description 2
- VIJNSDBCMJRPCN-GQOXECLESA-N CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VIJNSDBCMJRPCN-GQOXECLESA-N 0.000 claims description 2
- IOVJAXHVQIGGLL-OFWQUVEVSA-N CC1=NN(C(=C1)C)C1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=NN(C(=C1)C)C1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 IOVJAXHVQIGGLL-OFWQUVEVSA-N 0.000 claims description 2
- CTLUQNIUBWNIMI-YMPVSJOXSA-N CS(=O)(=O)N1CC(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CS(=O)(=O)N1CC(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 CTLUQNIUBWNIMI-YMPVSJOXSA-N 0.000 claims description 2
- GZGQFDYXPIMJJH-DLUKIOLESA-N FC1=C(C=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC1=C(C=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GZGQFDYXPIMJJH-DLUKIOLESA-N 0.000 claims description 2
- ZERWGBHYOAOFGK-BGERDNNASA-N OC(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 Chemical compound OC(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 ZERWGBHYOAOFGK-BGERDNNASA-N 0.000 claims description 2
- OGSHYTYJGZHOPP-UDJZJCJKSA-N OCC[C@@H](C(O)=O)N(C1CC(CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 Chemical compound OCC[C@@H](C(O)=O)N(C1CC(CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 OGSHYTYJGZHOPP-UDJZJCJKSA-N 0.000 claims description 2
- 150000001555 benzenes Chemical group 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- DASPXDAOECXGLI-SISMUFEVSA-N (2S)-2-(4,5,6,7-tetrahydro-1H-indazole-6-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1CCC=2C=NNC=2C1)C(=O)O DASPXDAOECXGLI-SISMUFEVSA-N 0.000 claims 1
- HTOWTDPFDXQLCY-SVIIMATRSA-N (2S)-2-(5,6,7,8-tetrahydronaphthalene-1-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1=CC=CC=2CCCCC1=2)C(=O)O HTOWTDPFDXQLCY-SVIIMATRSA-N 0.000 claims 1
- VXJZZVJKVRXUJG-DEOSSOPVSA-N (2S)-2-(5,6,7,8-tetrahydronaphthalene-1-carbonylamino)-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCCCOCC[C@H](NC(=O)C1=CC=CC=2CCCCC1=2)C(=O)O VXJZZVJKVRXUJG-DEOSSOPVSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- VSMAWKFGJPMWAT-UHFFFAOYSA-N 2-(2-phenylpropanoylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)C(C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C VSMAWKFGJPMWAT-UHFFFAOYSA-N 0.000 claims 1
- PFXQOSXLXHIHFO-UHFFFAOYSA-N 2-(3,3-dimethylbutanoylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound CC(CC(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C PFXQOSXLXHIHFO-UHFFFAOYSA-N 0.000 claims 1
- XOFKUKVGCUQGHA-UHFFFAOYSA-N 2-(3,4,5,6,7,7a-hexahydro-2H-1-benzofuran-3a-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound O1CCC2(C1CCCC2)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 XOFKUKVGCUQGHA-UHFFFAOYSA-N 0.000 claims 1
- MOIDYRBVDBEGGG-UHFFFAOYSA-N 2-(pyrimidin-4-ylamino)-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound N1=CN=C(C=C1)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1 MOIDYRBVDBEGGG-UHFFFAOYSA-N 0.000 claims 1
- DDAMGDFYVCARKH-UHFFFAOYSA-N 2-[(1-cyclopropylcyclopropanecarbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(CC1)C1(CC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 DDAMGDFYVCARKH-UHFFFAOYSA-N 0.000 claims 1
- QRLBGUXTMDORFW-UHFFFAOYSA-N 2-[(1-methylindazole-4-carbonyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound CN1N=CC=2C(=CC=CC1=2)C(=O)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1 QRLBGUXTMDORFW-UHFFFAOYSA-N 0.000 claims 1
- NMAYEJUARMKEBE-UHFFFAOYSA-N 2-[(1-methylindazole-4-carbonyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]hexanoic acid Chemical compound CN1N=CC=2C(=CC=CC1=2)C(=O)NC(C(=O)O)CCCCOCCC1=NC=2NCCCC=2C=C1 NMAYEJUARMKEBE-UHFFFAOYSA-N 0.000 claims 1
- VEIIQZKYUXJFDB-UHFFFAOYSA-N 2-[(2,4-dimethylpyridine-3-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound CC1=NC=CC(=C1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)C VEIIQZKYUXJFDB-UHFFFAOYSA-N 0.000 claims 1
- KHIIFNJWHRXDDA-UHFFFAOYSA-N 2-[(2-hydroxy-1,3-dihydroindene-2-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound OC1(CC2=CC=CC=C2C1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 KHIIFNJWHRXDDA-UHFFFAOYSA-N 0.000 claims 1
- XQNZWCJSKNDUJC-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound C(C)(C)(C)OC(=O)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1 XQNZWCJSKNDUJC-UHFFFAOYSA-N 0.000 claims 1
- KOENVOLWGFUKFS-UHFFFAOYSA-N 2-[(2-phenylacetyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)CC(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 KOENVOLWGFUKFS-UHFFFAOYSA-N 0.000 claims 1
- JNVPABCBBFKNRK-UHFFFAOYSA-N 2-[(3,5-dichloropyridine-4-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)Cl JNVPABCBBFKNRK-UHFFFAOYSA-N 0.000 claims 1
- LBQLMZKHUKBZCW-UHFFFAOYSA-N 2-[(3,6-dimethylpyridine-2-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound CC=1C(=NC(=CC=1)C)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 LBQLMZKHUKBZCW-UHFFFAOYSA-N 0.000 claims 1
- QSXIDMFPMPCZTD-UHFFFAOYSA-N 2-[(3-chloro-5-fluoropyridine-4-carbonyl)amino]-4-[2-hydroxy-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCC(CCC1=NC=2NCCCC=2C=C1)O)F QSXIDMFPMPCZTD-UHFFFAOYSA-N 0.000 claims 1
- CLXOUWREWNHRAF-UHFFFAOYSA-N 2-[(3-chloro-5-fluoropyridine-4-carbonyl)amino]-4-[2-methyl-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCC(CCC1=NC=2NCCCC=2C=C1)C)F CLXOUWREWNHRAF-UHFFFAOYSA-N 0.000 claims 1
- XONXGUNEGARHQV-UHFFFAOYSA-N 2-[(3-chloro-5-fluoropyridine-4-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)F XONXGUNEGARHQV-UHFFFAOYSA-N 0.000 claims 1
- YOUKWNQRORFDIC-UHFFFAOYSA-N 2-[(3-chloro-5-methoxypyridine-4-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)OC YOUKWNQRORFDIC-UHFFFAOYSA-N 0.000 claims 1
- MEAZBQPUFLWFME-UHFFFAOYSA-N 2-[(3-chloro-5-methylpyridine-4-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C MEAZBQPUFLWFME-UHFFFAOYSA-N 0.000 claims 1
- ZORNTFCVYPXCJZ-UHFFFAOYSA-N 2-[(3-chloro-5-methylpyridine-4-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)C ZORNTFCVYPXCJZ-UHFFFAOYSA-N 0.000 claims 1
- OFXVLIWLEVWDIY-UHFFFAOYSA-N 2-[(4,4-difluoro-3,3-dimethylbutanoyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound FC(C(CC(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C)F OFXVLIWLEVWDIY-UHFFFAOYSA-N 0.000 claims 1
- QZCURXWQZJSMBB-UHFFFAOYSA-N 2-[(4-chloro-2-methylpyrazole-3-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC1=C(N(N=C1)C)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 QZCURXWQZJSMBB-UHFFFAOYSA-N 0.000 claims 1
- UBFUFLJDCPKNSR-UHFFFAOYSA-N 2-[(6-methoxy-2,4-dimethylpyridine-3-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound COC1=CC(=C(C(=N1)C)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C UBFUFLJDCPKNSR-UHFFFAOYSA-N 0.000 claims 1
- CXPMGHJWQVHHDL-UHFFFAOYSA-N 2-[[1-(2-phenylethyl)cyclopropanecarbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)CCC1(CC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 CXPMGHJWQVHHDL-UHFFFAOYSA-N 0.000 claims 1
- IZQDHESAARVSFL-UHFFFAOYSA-N 2-[[1-(4-propan-2-ylphenyl)cyclopentanecarbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C(C)(C)C1=CC=C(C=C1)C1(CCCC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 IZQDHESAARVSFL-UHFFFAOYSA-N 0.000 claims 1
- ZPUWZEMTYNVIHD-UHFFFAOYSA-N 2-[[1-(benzenesulfonyl)cyclopropanecarbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)S(=O)(=O)C1(CC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 ZPUWZEMTYNVIHD-UHFFFAOYSA-N 0.000 claims 1
- XUGCNROOVFMBEQ-UHFFFAOYSA-N 2-[[3-(difluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound FC(C1=NN=C2N1CC(CC2)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)F XUGCNROOVFMBEQ-UHFFFAOYSA-N 0.000 claims 1
- CZPHVWOMNQNSJT-UHFFFAOYSA-N 2-[[5-chloro-3-fluoro-2-[(4-methylpiperazin-1-yl)methyl]pyridine-4-carbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC=1C(=C(C(=NC=1)CN1CCN(CC1)C)F)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 CZPHVWOMNQNSJT-UHFFFAOYSA-N 0.000 claims 1
- CLZXTIJSAYKCAB-UHFFFAOYSA-N 3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C(C)(C)(C)OC(=O)NC(C(=O)O)C(COC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C CLZXTIJSAYKCAB-UHFFFAOYSA-N 0.000 claims 1
- JYRGWUWUZOHHFE-UHFFFAOYSA-N 4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[(4,4,4-trifluoro-3,3-dimethylbutanoyl)amino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCCC(C(=O)O)NC(CC(C(F)(F)F)(C)C)=O JYRGWUWUZOHHFE-UHFFFAOYSA-N 0.000 claims 1
- TYIXUOALCOZMFC-UHFFFAOYSA-N 4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[2-[3-(trifluoromethyl)phenyl]butanoylamino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCCC(C(=O)O)NC(C(CC)C1=CC(=CC=C1)C(F)(F)F)=O TYIXUOALCOZMFC-UHFFFAOYSA-N 0.000 claims 1
- GXTWFQYNXNARPJ-GQOXECLESA-N C(C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GXTWFQYNXNARPJ-GQOXECLESA-N 0.000 claims 1
- VYAARYHYWCFSAN-IOYBJCICSA-N C(C)(=O)N1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)N1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VYAARYHYWCFSAN-IOYBJCICSA-N 0.000 claims 1
- POBPHCHGCFBIKE-UDJZJCJKSA-N C(C)(=O)N1CCC(CC1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C(F)(F)F Chemical compound C(C)(=O)N1CCC(CC1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C(F)(F)F POBPHCHGCFBIKE-UDJZJCJKSA-N 0.000 claims 1
- UHDLWURXFYPWIQ-JITJBCMDSA-N C(C)(C)(C)C1=CC(=NC=N1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=CC(=NC=N1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UHDLWURXFYPWIQ-JITJBCMDSA-N 0.000 claims 1
- UIHCENIFBSVKGV-SUIMDOTNSA-N C(C)(C)(C)C1=CC=C(C=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UIHCENIFBSVKGV-SUIMDOTNSA-N 0.000 claims 1
- BARUQCVHHKWWOK-JITJBCMDSA-N C(C)(C)(C)C1=NC(=NC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=NC(=NC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 BARUQCVHHKWWOK-JITJBCMDSA-N 0.000 claims 1
- WYWRUFCRPPVSHF-OFHXQBPLSA-N C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC(=CC=C1)Cl)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC(=CC=C1)Cl)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WYWRUFCRPPVSHF-OFHXQBPLSA-N 0.000 claims 1
- DXCSJGCPMCKFRB-IFVGDZTKSA-N C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC=C(C=C1)C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC=C(C=C1)C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 DXCSJGCPMCKFRB-IFVGDZTKSA-N 0.000 claims 1
- IDILDPDDIFRSTD-IVXJCAOYSA-N C(C)(C)(C)OC(=O)N1CC(C1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 IDILDPDDIFRSTD-IVXJCAOYSA-N 0.000 claims 1
- XVUTVZNWVYKENY-FTVZZTLYSA-N C(C)(C)(C)OC(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 XVUTVZNWVYKENY-FTVZZTLYSA-N 0.000 claims 1
- GQNWKHDCWYQXTN-TVNWEXPRSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GQNWKHDCWYQXTN-TVNWEXPRSA-N 0.000 claims 1
- SMBAYWITXKRDBX-PPSBMQLTSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 SMBAYWITXKRDBX-PPSBMQLTSA-N 0.000 claims 1
- MNDXAZJWZIDPQQ-KRWDZBQOSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 MNDXAZJWZIDPQQ-KRWDZBQOSA-N 0.000 claims 1
- QBPDYLDQLRALMX-FNEQHPHYSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC)C1=CC=CC=C1 Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC)C1=CC=CC=C1 QBPDYLDQLRALMX-FNEQHPHYSA-N 0.000 claims 1
- RDGRYSJHGSRVCD-RTJZXMOCSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)(F)F Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)(F)F RDGRYSJHGSRVCD-RTJZXMOCSA-N 0.000 claims 1
- AMBUMIMMNKTIOX-RTJZXMOCSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)F Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)F AMBUMIMMNKTIOX-RTJZXMOCSA-N 0.000 claims 1
- SLBFFHDHUBQANA-GHXXTNBWSA-N C1(=CC=CC=C1)C#CC1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C#CC1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 SLBFFHDHUBQANA-GHXXTNBWSA-N 0.000 claims 1
- OJCLQCHWOMDLBC-TVNWEXPRSA-N C1(=CC=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 OJCLQCHWOMDLBC-TVNWEXPRSA-N 0.000 claims 1
- LCPBVRSQFVUNFL-VZTJNBFISA-N C1(=CC=CC=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 LCPBVRSQFVUNFL-VZTJNBFISA-N 0.000 claims 1
- OHKKXIWLUQGAHT-SNYWLETKSA-N C1(=CC=CC=C1)C1C(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1C(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 OHKKXIWLUQGAHT-SNYWLETKSA-N 0.000 claims 1
- UWEPIOVHLSILOP-OFENFNCUSA-N C1(=CC=CC=C1)C1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UWEPIOVHLSILOP-OFENFNCUSA-N 0.000 claims 1
- ZQNPKOMNCWTCSI-ZZXNFCGKSA-N C1(=CC=CC=C1)C1CCC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1CCC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 ZQNPKOMNCWTCSI-ZZXNFCGKSA-N 0.000 claims 1
- MHRLNIRFYBTFOW-KABUSDLNSA-N C1(=CC=CC=C1)S(=O)(=O)N1C(CCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C(CCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 MHRLNIRFYBTFOW-KABUSDLNSA-N 0.000 claims 1
- OKZTWQDCTLHWLJ-WISNAQHKSA-N C1(=NC=CC2=CC=CC=C12)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=NC=CC2=CC=CC=C12)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 OKZTWQDCTLHWLJ-WISNAQHKSA-N 0.000 claims 1
- WLKLCAFBUHSOLW-RPRDLGQTSA-N C1(CCC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(CCC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WLKLCAFBUHSOLW-RPRDLGQTSA-N 0.000 claims 1
- FZFLEGZAKAYNKU-TVNWEXPRSA-N C1(CCCCC1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound C1(CCCCC1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C FZFLEGZAKAYNKU-TVNWEXPRSA-N 0.000 claims 1
- VOZVREDUXSLKJJ-QVHXHXEWSA-N C1(CCCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(CCCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VOZVREDUXSLKJJ-QVHXHXEWSA-N 0.000 claims 1
- UVEVOEWCTAJQIW-VHNLKAGOSA-N C1C(CC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1C(CC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UVEVOEWCTAJQIW-VHNLKAGOSA-N 0.000 claims 1
- VPIBBCIATCRMMJ-CKRJSAQMSA-N CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C=1C=NC=CC=1 Chemical compound CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C=1C=NC=CC=1 VPIBBCIATCRMMJ-CKRJSAQMSA-N 0.000 claims 1
- XQNFATHDIXSFHR-GQOXECLESA-N CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C XQNFATHDIXSFHR-GQOXECLESA-N 0.000 claims 1
- WLDIMVJRSOKMOU-PPSBMQLTSA-N CC1(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WLDIMVJRSOKMOU-PPSBMQLTSA-N 0.000 claims 1
- RVGBNDIUVIHOSC-FMKHTLPYSA-N CC1(CC2=CC=CC=C2CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CC2=CC=CC=C2CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 RVGBNDIUVIHOSC-FMKHTLPYSA-N 0.000 claims 1
- CSVCDQIWUAFCEE-PPSBMQLTSA-N CC1(CNC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CNC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 CSVCDQIWUAFCEE-PPSBMQLTSA-N 0.000 claims 1
- QZOXUGZFCFRNOG-DLUKIOLESA-N CC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 QZOXUGZFCFRNOG-DLUKIOLESA-N 0.000 claims 1
- IZJQTCLKUCAEFC-FNEQHPHYSA-N CC1=CC=C2CCN(C2=C1)C(=O)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=CC=C2CCN(C2=C1)C(=O)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 IZJQTCLKUCAEFC-FNEQHPHYSA-N 0.000 claims 1
- DNACQJHSVPUEQW-TXSRUQCCSA-N CC1N(C(CC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(CC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 DNACQJHSVPUEQW-TXSRUQCCSA-N 0.000 claims 1
- WBHQLHVBEMJXGC-XRUJOLSKSA-N CC1N(C(CCC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(CCC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WBHQLHVBEMJXGC-XRUJOLSKSA-N 0.000 claims 1
- UKTAHNIUWONWLR-TXSRUQCCSA-N CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UKTAHNIUWONWLR-TXSRUQCCSA-N 0.000 claims 1
- ZWPRMFJVYGKWDT-UHYCVJNDSA-N CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 ZWPRMFJVYGKWDT-UHYCVJNDSA-N 0.000 claims 1
- DRDABHKCNJEODO-DFTBRHRKSA-N CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O)C1=CC=CC=C1 Chemical compound CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O)C1=CC=CC=C1 DRDABHKCNJEODO-DFTBRHRKSA-N 0.000 claims 1
- RSASWOQVVVQPOG-JITJBCMDSA-N CC=1NC(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O Chemical compound CC=1NC(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O RSASWOQVVVQPOG-JITJBCMDSA-N 0.000 claims 1
- JMIGLWUNTMGMCN-MLFGXNJISA-N CN1C=CC2=C1N=CC=C2C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CN1C=CC2=C1N=CC=C2C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 JMIGLWUNTMGMCN-MLFGXNJISA-N 0.000 claims 1
- MGMJYAQAWGTHPC-PYPWZVKOSA-N CN1N=CC(=C1)C1(OCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CN1N=CC(=C1)C1(OCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 MGMJYAQAWGTHPC-PYPWZVKOSA-N 0.000 claims 1
- GELIGEIZZSEFKG-KGGRFHARSA-N CN1N=CC=2C(=CC=CC1=2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CN1N=CC=2C(=CC=CC1=2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GELIGEIZZSEFKG-KGGRFHARSA-N 0.000 claims 1
- WHISAKVEOBGUAL-GQOXECLESA-N CS(=O)(=O)CCCC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CS(=O)(=O)CCCC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WHISAKVEOBGUAL-GQOXECLESA-N 0.000 claims 1
- JPDIZYLISXTLOT-IIXJVVKQSA-N FC1(C(C1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C=1C=C(C=CC=1)C)F Chemical compound FC1(C(C1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C=1C=C(C=CC=1)C)F JPDIZYLISXTLOT-IIXJVVKQSA-N 0.000 claims 1
- LJEJTLIARYAJLR-NZBFNNPHSA-N FC1=C2C(=NC=NC2=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC1=C2C(=NC=NC2=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 LJEJTLIARYAJLR-NZBFNNPHSA-N 0.000 claims 1
- GDFKDOSBEGSKIM-WQMGSUCASA-N FC1=CC=C(C=C1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound FC1=CC=C(C=C1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C GDFKDOSBEGSKIM-WQMGSUCASA-N 0.000 claims 1
- NVAMWQKQQAKAPM-JCJCGPQSSA-N FC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 NVAMWQKQQAKAPM-JCJCGPQSSA-N 0.000 claims 1
- NNDQOPUAFXNWTH-NZBFNNPHSA-N FC=1C=CC=C2C(=NC=NC=12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC=1C=CC=C2C(=NC=NC=12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 NNDQOPUAFXNWTH-NZBFNNPHSA-N 0.000 claims 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims 1
- WXXQWIROHMGNTF-MLFGXNJISA-N N1=CN=C(C2=CC=CC=C12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1=CN=C(C2=CC=CC=C12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WXXQWIROHMGNTF-MLFGXNJISA-N 0.000 claims 1
- ARMCZHYGPCXDNO-NZBFNNPHSA-N N1C=CC2=NC=CC(=C21)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1C=CC2=NC=CC(=C21)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 ARMCZHYGPCXDNO-NZBFNNPHSA-N 0.000 claims 1
- VBZPROHBRBAQHR-DJKWIZAZSA-N N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VBZPROHBRBAQHR-DJKWIZAZSA-N 0.000 claims 1
- XXXPKNDJLXPIEL-PPSBMQLTSA-N OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C XXXPKNDJLXPIEL-PPSBMQLTSA-N 0.000 claims 1
- HCVJTCWUULLGEU-OIYWLGGTSA-N OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 Chemical compound OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 HCVJTCWUULLGEU-OIYWLGGTSA-N 0.000 claims 1
- SNVCQQCZLNQNCH-MOQPWLNLSA-N OCC[C@@H](C(O)=O)NC1CC(CCC2=NC(NCCC3)=C3C=C2)C1 Chemical compound OCC[C@@H](C(O)=O)NC1CC(CCC2=NC(NCCC3)=C3C=C2)C1 SNVCQQCZLNQNCH-MOQPWLNLSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract description 11
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 204
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 143
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 124
- 125000006413 ring segment Chemical group 0.000 description 76
- 125000004432 carbon atom Chemical group C* 0.000 description 72
- 238000006243 chemical reaction Methods 0.000 description 54
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 31
- 239000002585 base Substances 0.000 description 31
- 239000010410 layer Substances 0.000 description 31
- 239000012071 phase Substances 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000460 chlorine Substances 0.000 description 26
- 229910052757 nitrogen Inorganic materials 0.000 description 26
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 22
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 125000005842 heteroatom Chemical group 0.000 description 20
- 239000012535 impurity Substances 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 125000001309 chloro group Chemical group Cl* 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- 229910052731 fluorine Inorganic materials 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 239000011734 sodium Substances 0.000 description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- QDMZCBABQCORRW-BYPYZUCNSA-N methyl (2s)-2-amino-4-hydroxybutanoate Chemical compound COC(=O)[C@@H](N)CCO QDMZCBABQCORRW-BYPYZUCNSA-N 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 229910052717 sulfur Chemical group 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 239000011593 sulfur Chemical group 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000004808 supercritical fluid chromatography Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- 239000012267 brine Substances 0.000 description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 229910004298 SiO 2 Inorganic materials 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000002993 cycloalkylene group Chemical group 0.000 description 9
- 230000008570 general process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- ATUUSOSLBXVJKL-UHFFFAOYSA-N 3-ethylpentanoic acid Chemical compound CCC(CC)CC(O)=O ATUUSOSLBXVJKL-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 125000004450 alkenylene group Chemical group 0.000 description 8
- 150000001350 alkyl halides Chemical class 0.000 description 8
- 125000004419 alkynylene group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000011737 fluorine Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 125000006574 non-aromatic ring group Chemical group 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- TUHPRPIQWXZJQE-UHFFFAOYSA-N 3-(1,3-thiazol-5-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2SC=NC=2)=C1 TUHPRPIQWXZJQE-UHFFFAOYSA-N 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000007937 lozenge Substances 0.000 description 7
- 238000007248 oxidative elimination reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- WJYAYXKXZNITAZ-UHFFFAOYSA-N 2-chloro-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1Cl WJYAYXKXZNITAZ-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 6
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 229940127271 compound 49 Drugs 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000026045 iodination Effects 0.000 description 6
- 238000006192 iodination reaction Methods 0.000 description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- QKAIIJHXZDNKMY-BYPYZUCNSA-N (2s)-4-hydroxy-2-(methylamino)butanoic acid Chemical compound CN[C@H](C(O)=O)CCO QKAIIJHXZDNKMY-BYPYZUCNSA-N 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 5
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 5
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 206010061989 glomerulosclerosis Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 238000006884 silylation reaction Methods 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 4
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 4
- JACRWUWPXAESPB-QMMMGPOBSA-N (R)-tropic acid Chemical compound OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 description 4
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- JBQMFBWTKWOSQX-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCC2=C1 JBQMFBWTKWOSQX-UHFFFAOYSA-N 0.000 description 4
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 4
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000872931 Myoporum sandwicense Species 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229940126545 compound 53 Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 4
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- 229940005605 valeric acid Drugs 0.000 description 4
- HDKWKDXEBFQOHD-NXEZZACHSA-N (1R,2R)-2-(3,5-dimethylpyrazol-1-yl)cyclopentan-1-ol Chemical compound Cc1cc(C)n(n1)[C@@H]1CCC[C@H]1O HDKWKDXEBFQOHD-NXEZZACHSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
- NXMFJCRMSDRXLD-UHFFFAOYSA-N 2-aminopyridine-3-carbaldehyde Chemical compound NC1=NC=CC=C1C=O NXMFJCRMSDRXLD-UHFFFAOYSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 3
- UKAUYVFTDYCKQA-GSVOUGTGSA-N D-homoserine Chemical compound OC(=O)[C@H](N)CCO UKAUYVFTDYCKQA-GSVOUGTGSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 229930182821 L-proline Natural products 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 3
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000010492 gellan gum Nutrition 0.000 description 3
- 239000000216 gellan gum Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 108010059115 integrin alpha11beta1 Proteins 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000036573 scar formation Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SIPPACGSOBTDRS-UHFFFAOYSA-N tert-butyl 3-hydroxy-3-(4-propan-2-ylphenyl)azetidine-1-carboxylate Chemical compound C1=CC(C(C)C)=CC=C1C1(O)CN(C(=O)OC(C)(C)C)C1 SIPPACGSOBTDRS-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229940126135 αvβ6 integrin inhibitor Drugs 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 2
- JACRWUWPXAESPB-MRVPVSSYSA-N (S)-tropic acid Chemical compound OC[C@@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-MRVPVSSYSA-N 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JHZRNLRTNIDFKG-UHFFFAOYSA-N 1-phenylcyclobutane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CCC1 JHZRNLRTNIDFKG-UHFFFAOYSA-N 0.000 description 2
- IWWCCNVRNHTGLV-UHFFFAOYSA-N 1-phenylcyclopropane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CC1 IWWCCNVRNHTGLV-UHFFFAOYSA-N 0.000 description 2
- BQHWATVEWGHHHF-UHFFFAOYSA-N 2,2-dimethyl-3-phenylpropanoic acid Chemical compound OC(=O)C(C)(C)CC1=CC=CC=C1 BQHWATVEWGHHHF-UHFFFAOYSA-N 0.000 description 2
- XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
- DTLIEBPGBUWODB-UHFFFAOYSA-N 2-(2-ethylbutanoylamino)-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound C(C)C(C(=O)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1)CC DTLIEBPGBUWODB-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IGPDGDPRWAYQSD-UHFFFAOYSA-N 2-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]acetaldehyde Chemical compound N1=C(C=CC=2CCCNC1=2)CCCCOCC=O IGPDGDPRWAYQSD-UHFFFAOYSA-N 0.000 description 2
- RTXDKVFNAOMDFV-UHFFFAOYSA-N 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetic acid Chemical compound COP(=O)(OC)C(C(O)=O)NC(=O)OCC1=CC=CC=C1 RTXDKVFNAOMDFV-UHFFFAOYSA-N 0.000 description 2
- YYEROYLAYAVZNW-UHFFFAOYSA-N 2-methyl-2-phenylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC=C1 YYEROYLAYAVZNW-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- XFOWYEKVIRMOBI-UHFFFAOYSA-N 3,3-dimethylbutanenitrile Chemical compound CC(C)(C)CC#N XFOWYEKVIRMOBI-UHFFFAOYSA-N 0.000 description 2
- FPENCTDAQQQKNY-UHFFFAOYSA-N 3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1 FPENCTDAQQQKNY-UHFFFAOYSA-N 0.000 description 2
- ADEBTUFPSZKNOA-UHFFFAOYSA-N 3-(1-methylpyrazol-4-yl)benzoic acid Chemical compound C1=NN(C)C=C1C1=CC=CC(C(O)=O)=C1 ADEBTUFPSZKNOA-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- NSGKIIGVPBTOBF-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(F)=CC(C(F)(F)F)=C1 NSGKIIGVPBTOBF-UHFFFAOYSA-N 0.000 description 2
- RDFQSFOGKVZWKF-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanoic acid Chemical compound OCC(C)(C)C(O)=O RDFQSFOGKVZWKF-UHFFFAOYSA-N 0.000 description 2
- FLFLSQGRBROAPA-UHFFFAOYSA-N 3-methoxy-2,2-dimethylpropanoic acid Chemical compound COCC(C)(C)C(O)=O FLFLSQGRBROAPA-UHFFFAOYSA-N 0.000 description 2
- PMPZEEUNGQSAIQ-UHFFFAOYSA-N 3-methyloxetane-3-carboxylic acid Chemical compound OC(=O)C1(C)COC1 PMPZEEUNGQSAIQ-UHFFFAOYSA-N 0.000 description 2
- MTLNUCHJTJRGOZ-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butan-1-ol Chemical compound C1CCNC2=NC(CCCCO)=CC=C21 MTLNUCHJTJRGOZ-UHFFFAOYSA-N 0.000 description 2
- RNQDBLUYYSHGRP-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanoic acid;hydrochloride Chemical compound Cl.C1CCNC2=NC(CCCC(=O)O)=CC=C21 RNQDBLUYYSHGRP-UHFFFAOYSA-N 0.000 description 2
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000238367 Mya arenaria Species 0.000 description 2
- SUKXKLNDBLNTSW-UHFFFAOYSA-N N-(4-hydroxycyclohexyl)-6-phenylhexanamide Chemical compound OC1CCC(CC1)NC(CCCCCC1=CC=CC=C1)=O SUKXKLNDBLNTSW-UHFFFAOYSA-N 0.000 description 2
- 229910017906 NH3H2O Inorganic materials 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- JACRWUWPXAESPB-UHFFFAOYSA-N S-tropic acid Natural products OCC(C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 210000004712 air sac Anatomy 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- OSUPUGFYHLNTLX-UHFFFAOYSA-N methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]but-2-enoate Chemical compound C(C)(C)(C)OC(=O)NC(C(=O)OC)=CCOCCCCC1=NC=2NCCCC=2C=C1 OSUPUGFYHLNTLX-UHFFFAOYSA-N 0.000 description 2
- LJHAPRKTPAREGO-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate Chemical compound COC(=O)C(P(=O)(OC)OC)NC(=O)OC(C)(C)C LJHAPRKTPAREGO-UHFFFAOYSA-N 0.000 description 2
- OJHUHKKURDTCEL-UHFFFAOYSA-N methyl 3-(1,3-thiazol-5-yl)benzoate Chemical compound COC(=O)C1=CC=CC(C=2SC=NC=2)=C1 OJHUHKKURDTCEL-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IDSMDKUVIBSETN-UHFFFAOYSA-N n-methyl-n-(propan-2-ylideneamino)methanamine Chemical compound CN(C)N=C(C)C IDSMDKUVIBSETN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003355 serines Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 239000001476 sodium potassium tartrate Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- KZXMKKSDVITCAY-UHFFFAOYSA-N tert-butyl 7-(4-hydroxybutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate Chemical compound OCCCCC1=CC=C2CCCN(C2=N1)C(=O)OC(C)(C)C KZXMKKSDVITCAY-UHFFFAOYSA-N 0.000 description 2
- UKKDZRGPGFGAJF-UHFFFAOYSA-N tert-butyl 7-(4-oxobutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCc2ccc(CCCC=O)nc12 UKKDZRGPGFGAJF-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LQUPKVMEAATBSL-UHFFFAOYSA-L zinc;2,3,4-trichlorophenolate Chemical compound [Zn+2].[O-]C1=CC=C(Cl)C(Cl)=C1Cl.[O-]C1=CC=C(Cl)C(Cl)=C1Cl LQUPKVMEAATBSL-UHFFFAOYSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GJEZBVHHZQAEDB-SYDPRGILSA-N (1s,5r)-6-oxabicyclo[3.1.0]hexane Chemical compound C1CC[C@H]2O[C@H]21 GJEZBVHHZQAEDB-SYDPRGILSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- TYQSPGDKGHTOLA-UHFFFAOYSA-N 1-methylindazole-4-carboxylic acid Chemical compound C1=CC=C2N(C)N=CC2=C1C(O)=O TYQSPGDKGHTOLA-UHFFFAOYSA-N 0.000 description 1
- FDPGPKFADPMZLJ-UHFFFAOYSA-N 1-methylpyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CN=C2N(C)C=CC2=C1C(O)=O FDPGPKFADPMZLJ-UHFFFAOYSA-N 0.000 description 1
- QAEFMEIYIBNWLW-UHFFFAOYSA-N 1-methylpyrrolo[2,3-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2N(C)C=CC2=C1 QAEFMEIYIBNWLW-UHFFFAOYSA-N 0.000 description 1
- JUUBFHLPTCPVBO-UHFFFAOYSA-N 2,2-dimethylpropyl carbonochloridate Chemical compound CC(C)(C)COC(Cl)=O JUUBFHLPTCPVBO-UHFFFAOYSA-N 0.000 description 1
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 1
- JLZVIWSFUPLSOR-UHFFFAOYSA-N 2,3-difluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1F JLZVIWSFUPLSOR-UHFFFAOYSA-N 0.000 description 1
- NJYBIFYEWYWYAN-UHFFFAOYSA-N 2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-N 0.000 description 1
- LBQMIAVIGLLBGW-UHFFFAOYSA-N 2,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1F LBQMIAVIGLLBGW-UHFFFAOYSA-N 0.000 description 1
- ONOTYLMNTZNAQZ-UHFFFAOYSA-N 2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1F ONOTYLMNTZNAQZ-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- MIZKCMSSYVUZKD-UHFFFAOYSA-N 2-chloro-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1Cl MIZKCMSSYVUZKD-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- NEWMOJFYPOJQIR-UHFFFAOYSA-N 2-cyclopropylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1CC1 NEWMOJFYPOJQIR-UHFFFAOYSA-N 0.000 description 1
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- HNFGGBMTWQVAED-UHFFFAOYSA-N 2-methylindazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=NN(C)C=C21 HNFGGBMTWQVAED-UHFFFAOYSA-N 0.000 description 1
- NVLCMLWKXVOTAJ-UHFFFAOYSA-N 2-methylindazole-6-carboxylic acid Chemical compound C1=CC(C(O)=O)=CC2=NN(C)C=C21 NVLCMLWKXVOTAJ-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VPHHJAOJUJHJKD-UHFFFAOYSA-N 3,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-N 0.000 description 1
- GONAVIHGXFBTOZ-UHFFFAOYSA-N 3,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(F)=C1 GONAVIHGXFBTOZ-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- UOKBFIOAEPCADP-UHFFFAOYSA-N 3-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=CC(C(O)=O)=C1 UOKBFIOAEPCADP-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- FCSSYEWURMTUSM-UHFFFAOYSA-N 3-chloro-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1F FCSSYEWURMTUSM-UHFFFAOYSA-N 0.000 description 1
- QFMRANWPGGSNHS-UHFFFAOYSA-N 3-chloro-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(Cl)=C1 QFMRANWPGGSNHS-UHFFFAOYSA-N 0.000 description 1
- RQRAQQYDNSRVRK-UHFFFAOYSA-N 3-cyclopropylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C2CC2)=C1 RQRAQQYDNSRVRK-UHFFFAOYSA-N 0.000 description 1
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 1
- GTTKZPZHIIAOOV-UHFFFAOYSA-N 3-hydroxy-3-methylazetidine-1-carboxylic acid Chemical compound CC1(O)CN(C(O)=O)C1 GTTKZPZHIIAOOV-UHFFFAOYSA-N 0.000 description 1
- HTHMVKNHGOVITA-UHFFFAOYSA-N 3-methylazetidine Chemical compound CC1CNC1 HTHMVKNHGOVITA-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HYIUDFLDFSIXTR-UHFFFAOYSA-N 4,4-difluorocyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCC(F)(F)CC1 HYIUDFLDFSIXTR-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 1
- GJCRWEAWEDESNZ-UHFFFAOYSA-N 4-cyclopropylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1CC1 GJCRWEAWEDESNZ-UHFFFAOYSA-N 0.000 description 1
- DWUPYMSVAPQXMS-UHFFFAOYSA-N 5-bromo-1,3-thiazole Chemical compound BrC1=CN=CS1 DWUPYMSVAPQXMS-UHFFFAOYSA-N 0.000 description 1
- LPNANKDXVBMDKE-UHFFFAOYSA-N 5-bromopent-1-ene Chemical compound BrCCCC=C LPNANKDXVBMDKE-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RDIRSUVDORCCOF-MUBNQFKJSA-N C(C)(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 RDIRSUVDORCCOF-MUBNQFKJSA-N 0.000 description 1
- QYQXQTPKEBMUOK-SFHVURJKSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)CCCCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)CCCCC1=NC=2NCCCC=2C=C1 QYQXQTPKEBMUOK-SFHVURJKSA-N 0.000 description 1
- LLJYKJQPYYHFKA-VDGAXYAQSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 LLJYKJQPYYHFKA-VDGAXYAQSA-N 0.000 description 1
- HEJZDXCGIJCELV-PPSBMQLTSA-N C(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 HEJZDXCGIJCELV-PPSBMQLTSA-N 0.000 description 1
- PDQXZMXGLYGIRI-LFNLJPBCSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC PDQXZMXGLYGIRI-LFNLJPBCSA-N 0.000 description 1
- JODDURWFYUYUGT-IBGZPJMESA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)CC Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)CC JODDURWFYUYUGT-IBGZPJMESA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
- CEZCJXAOLZCCQP-YYWHXJBOSA-N CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 CEZCJXAOLZCCQP-YYWHXJBOSA-N 0.000 description 1
- KJSFXFXAEBFCPL-XPTLERTKSA-N CC1=NN(C(=C1)C)C1C(CCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=NN(C(=C1)C)C1C(CCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 KJSFXFXAEBFCPL-XPTLERTKSA-N 0.000 description 1
- FAOTXHNAHTVFNU-FQEVSTJZSA-N CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C)=O)CC(F)(F)F Chemical compound CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C)=O)CC(F)(F)F FAOTXHNAHTVFNU-FQEVSTJZSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- XEAZTQGMTUJPPO-JSTHURLESA-N Cl.Cl.N1=C(C=CC=2CCCNC1=2)CC[C@@H]1C[C@H](C1)OCC[C@H](N)C(=O)OC Chemical compound Cl.Cl.N1=C(C=CC=2CCCNC1=2)CC[C@@H]1C[C@H](C1)OCC[C@H](N)C(=O)OC XEAZTQGMTUJPPO-JSTHURLESA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- GMEONFUTDYJSNV-UHFFFAOYSA-N Ethyl levulinate Chemical compound CCOC(=O)CCC(C)=O GMEONFUTDYJSNV-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- VPDVTEFLBYBLPH-MTQWGCILSA-N N1=C(C=CC=C1)C1(CC2(C1)CCC2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1=C(C=CC=C1)C1(CC2(C1)CCC2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VPDVTEFLBYBLPH-MTQWGCILSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- STQFFMUUJGXUMA-FNEQHPHYSA-N O1COC2=C1C=CC(=C2)C1(CCCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound O1COC2=C1C=CC(=C2)C1(CCCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 STQFFMUUJGXUMA-FNEQHPHYSA-N 0.000 description 1
- OGSHYTYJGZHOPP-STZQEDGTSA-N OCC[C@H](C(O)=O)N([C@H]1C[C@H](CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 Chemical compound OCC[C@H](C(O)=O)N([C@H]1C[C@H](CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 OGSHYTYJGZHOPP-STZQEDGTSA-N 0.000 description 1
- ZERWGBHYOAOFGK-NHCUHLMSSA-N O[C@@H](C(=O)ON([C@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 Chemical compound O[C@@H](C(=O)ON([C@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 ZERWGBHYOAOFGK-NHCUHLMSSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- VLHDTCQJXYKEJT-UHFFFAOYSA-M [Br-].CC(C)C1=CC=C([Mg+])C=C1 Chemical compound [Br-].CC(C)C1=CC=C([Mg+])C=C1 VLHDTCQJXYKEJT-UHFFFAOYSA-M 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- JYFJNCCRKBBRKZ-UHFFFAOYSA-N chembl194764 Chemical compound C=1C=CC=C(F)C=1CCN1C(=O)C(CC)=C(C)N=C1C1=CC=CC=C1O JYFJNCCRKBBRKZ-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OBUNGSYDZFJRIU-UHFFFAOYSA-N chloromethane;n-ethylethanamine Chemical compound ClC.CCNCC OBUNGSYDZFJRIU-UHFFFAOYSA-N 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- MXWRJMIKMODSCY-UHFFFAOYSA-N ethane;dihydrochloride Chemical compound Cl.Cl.CC MXWRJMIKMODSCY-UHFFFAOYSA-N 0.000 description 1
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000012955 familial cardiomyopathy Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 1
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 1
- MCVVUJPXSBQTRZ-UHFFFAOYSA-N methyl but-2-enoate Chemical compound COC(=O)C=CC MCVVUJPXSBQTRZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005574 norbornylene group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000004260 quinazolin-2-yl group Chemical group [H]C1=NC(*)=NC2=C1C([H])=C([H])C([H])=C2[H] 0.000 description 1
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 1
- RAYMXZBXQCGRGX-UHFFFAOYSA-N quinoline-5-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=N1 RAYMXZBXQCGRGX-UHFFFAOYSA-N 0.000 description 1
- VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 description 1
- WXXVQWSDMOAHHV-UHFFFAOYSA-N quinoline-7-carboxylic acid Chemical compound C1=CC=NC2=CC(C(=O)O)=CC=C21 WXXVQWSDMOAHHV-UHFFFAOYSA-N 0.000 description 1
- QRDZFPUVLYEQTA-UHFFFAOYSA-N quinoline-8-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC=CC2=C1 QRDZFPUVLYEQTA-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742901P | 2018-10-08 | 2018-10-08 | |
| US62/742,901 | 2018-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202028179A true TW202028179A (zh) | 2020-08-01 |
Family
ID=70051340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108136254A TW202028179A (zh) | 2018-10-08 | 2019-10-07 | 胺基酸化合物及使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11180494B2 (https=) |
| EP (1) | EP3863711A4 (https=) |
| JP (1) | JP7523450B2 (https=) |
| KR (1) | KR20210101205A (https=) |
| CN (1) | CN113195053B (https=) |
| AU (1) | AU2019358041A1 (https=) |
| BR (1) | BR112021006620A2 (https=) |
| CA (1) | CA3115643A1 (https=) |
| CL (2) | CL2021000863A1 (https=) |
| CO (1) | CO2021004279A2 (https=) |
| CR (1) | CR20210224A (https=) |
| CU (1) | CU24690B1 (https=) |
| DO (1) | DOP2021000054A (https=) |
| EA (1) | EA202190967A1 (https=) |
| EC (1) | ECSP21032717A (https=) |
| IL (1) | IL282026A (https=) |
| JO (1) | JOP20210056A1 (https=) |
| MX (1) | MX2021004015A (https=) |
| PE (1) | PE20211463A1 (https=) |
| PH (1) | PH12021550784A1 (https=) |
| SG (1) | SG11202103283RA (https=) |
| TW (1) | TW202028179A (https=) |
| WO (1) | WO2020076862A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| FI3761980T3 (fi) | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| GB202010626D0 (en) * | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| EP4247472A4 (en) | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| IL321740A (en) * | 2022-12-27 | 2025-08-01 | Pliant Therapeutics Inc | Alpha-V-beta-8 integrin inhibitors and their uses |
| GB202301024D0 (en) * | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| WO2025130549A1 (zh) * | 2023-12-22 | 2025-06-26 | 北京炫景瑞医药科技有限公司 | 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| CN101784516B (zh) | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
| US20120289481A1 (en) * | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| BR112017020484B1 (pt) * | 2015-03-25 | 2023-03-28 | Fujifilm Corporation | Métodos para fabricar um composto contendo nitrogênio ou sal do mesmo e um complexo metálico, compostos contendo nitrogênio, complexos dos ditos compostos e composições farmacêuticas compreendendo os ditos complexos |
| US11192889B2 (en) | 2016-07-05 | 2021-12-07 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| ES2984394T3 (es) | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| FI3761980T3 (fi) | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| CN115989235A (zh) | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
-
2019
- 2019-10-07 TW TW108136254A patent/TW202028179A/zh unknown
- 2019-10-08 US US16/596,649 patent/US11180494B2/en active Active
- 2019-10-08 WO PCT/US2019/055252 patent/WO2020076862A1/en not_active Ceased
- 2019-10-08 AU AU2019358041A patent/AU2019358041A1/en not_active Abandoned
- 2019-10-08 KR KR1020217013781A patent/KR20210101205A/ko not_active Ceased
- 2019-10-08 SG SG11202103283RA patent/SG11202103283RA/en unknown
- 2019-10-08 MX MX2021004015A patent/MX2021004015A/es unknown
- 2019-10-08 CU CU2021000027A patent/CU24690B1/es unknown
- 2019-10-08 CA CA3115643A patent/CA3115643A1/en active Pending
- 2019-10-08 PE PE2021000461A patent/PE20211463A1/es unknown
- 2019-10-08 CN CN201980066146.7A patent/CN113195053B/zh active Active
- 2019-10-08 BR BR112021006620A patent/BR112021006620A2/pt unknown
- 2019-10-08 JO JOP/2021/0056A patent/JOP20210056A1/ar unknown
- 2019-10-08 EP EP19870448.8A patent/EP3863711A4/en not_active Withdrawn
- 2019-10-08 JP JP2021544112A patent/JP7523450B2/ja active Active
- 2019-10-08 CR CR20210224A patent/CR20210224A/es unknown
- 2019-10-08 EA EA202190967A patent/EA202190967A1/ru unknown
-
2021
- 2021-03-30 DO DO2021000054A patent/DOP2021000054A/es unknown
- 2021-04-04 IL IL282026A patent/IL282026A/en unknown
- 2021-04-07 CO CONC2021/0004279A patent/CO2021004279A2/es unknown
- 2021-04-07 CL CL2021000863A patent/CL2021000863A1/es unknown
- 2021-04-08 PH PH12021550784A patent/PH12021550784A1/en unknown
- 2021-05-07 EC ECSENADI202132717A patent/ECSP21032717A/es unknown
- 2021-10-18 US US17/504,384 patent/US11952376B2/en active Active
-
2023
- 2023-05-08 CL CL2023001331A patent/CL2023001331A1/es unknown
- 2023-12-19 US US18/545,952 patent/US20240270742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000054A (es) | 2021-08-31 |
| JP2022508657A (ja) | 2022-01-19 |
| ECSP21032717A (es) | 2021-06-30 |
| MX2021004015A (es) | 2021-06-23 |
| EA202190967A1 (ru) | 2021-09-17 |
| CA3115643A1 (en) | 2020-04-16 |
| CL2021000863A1 (es) | 2021-09-10 |
| US11952376B2 (en) | 2024-04-09 |
| EP3863711A4 (en) | 2022-07-06 |
| KR20210101205A (ko) | 2021-08-18 |
| US20240270742A1 (en) | 2024-08-15 |
| US20200109141A1 (en) | 2020-04-09 |
| JOP20210056A1 (ar) | 2021-03-24 |
| CO2021004279A2 (es) | 2021-04-30 |
| CN113195053B (zh) | 2024-08-30 |
| CN113195053A (zh) | 2021-07-30 |
| IL282026A (en) | 2021-05-31 |
| PE20211463A1 (es) | 2021-08-05 |
| WO2020076862A1 (en) | 2020-04-16 |
| CU24690B1 (es) | 2023-12-07 |
| US20220144829A1 (en) | 2022-05-12 |
| CU20210027A7 (es) | 2021-11-04 |
| JP7523450B2 (ja) | 2024-07-26 |
| AU2019358041A1 (en) | 2021-05-20 |
| US11180494B2 (en) | 2021-11-23 |
| EP3863711A1 (en) | 2021-08-18 |
| PH12021550784A1 (en) | 2021-10-25 |
| CR20210224A (es) | 2021-06-08 |
| BR112021006620A2 (pt) | 2021-07-06 |
| SG11202103283RA (en) | 2021-04-29 |
| CL2023001331A1 (es) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202028179A (zh) | 胺基酸化合物及使用方法 | |
| TWI841573B (zh) | 具有未分支連接子之胺基酸化合物及使用方法 | |
| AU2018392321B2 (en) | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | |
| ES3036122T3 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| JP7271557B2 (ja) | Ｉｌ－１７モジュレータとしての縮合イミダゾール誘導体 | |
| ES3058680T3 (en) | Cyclohexyl acid isoxazole azines as lpa antagonists | |
| ES2938863T3 (es) | Triazol azoles de ácido ciclohexilo como antagonistas de ácido lisofosfatídico (LPA) | |
| TW202204340A (zh) | Lpa受體拮抗劑及其用途 | |
| CA3042710A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors | |
| JP2024519496A (ja) | ブルトンのチロシンキナーゼの分解を標的化するための化合物 | |
| TW201040166A (en) | Isoxazol-3(2H)-one analogs as therapeutic agents | |
| JP2022500470A (ja) | Ｌｐａアンタゴニストとしてのシクロペンチル酸 | |
| CN114728958A (zh) | Rip1抑制性化合物和制备与使用其的方法 | |
| BR122023025996A2 (pt) | Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção | |
| HK40057175A (en) | Amino acid compounds and methods of use | |
| HK40049583A (en) | Amino acid compounds with unbranched linkers and methods of use | |
| TW202542145A (zh) | Smyd調節劑及其用途 | |
| NZ750013A (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |